CIK: 0001687078 · Show all filings
Period: Q2 2023 (← Previous) (Next →)
Filing Date: Aug 14, 2023
Total Value ($000): $496,603 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | 7,648,268 | $82,295 | 16.6% | $40.60 | -73.8% | Common | 230031106 |
| — | Iveric Bio Inc | 1,214,662 | $47,785 | 9.6% | $20.92 | — | Common | 46583P102 |
| — | Chinook Therapeutics, Inc. | 1,003,406 | $38,551 | 7.8% | $35.65 | — | Common | 16961L106 |
| GERN | Geron Corporation | 9,191,290 | $29,504 | 5.9% | $1.47 | +93.4% | Common | 374163103 |
| — | Reata Pharmaceuticals, Inc. | 234,478 | $23,907 | 4.8% | $50.07 | — | Common | 75615P103 |
| — | iTeos Therapeutics, Inc. | 1,745,943 | $23,116 | 4.7% | $24.67 | — | Common | 46565G104 |
| NTLA | Intellia Therapeutics, Inc. | 544,639 | $22,210 | 4.5% | $77.45 | -47.6% | Common | 45826J105 |
| IOVA | Iovance Biotherapeutics Inc | 2,950,118 | $20,769 | 4.2% | $10.38 | -31.0% | Common | 462260100 |
| — | Repare Therapeutics, Inc. | 1,639,849 | $17,350 | 3.5% | $31.02 | — | Common | 760273102 |
| RLAY | Relay Therapeutics Inc. | 1,354,368 | $17,011 | 3.4% | $17.41 | -28.6% | Common | 75943R102 |
| — | Verve Therapeutics, Inc | 857,940 | $16,086 | 3.2% | $30.36 | — | Common | 92539P101 |
| MLTX | Moonlake Immunotherapeutics | 295,111 | $15,051 | 3.0% | $26.91 | 0.0% | Common | 61559X104 |
| RGNX | REGENXBIO Inc. | 656,718 | $13,128 | 2.6% | $29.05 | -33.7% | Common | 75901B107 |
| — | Karuna Therapeutics Inc | 53,399 | $11,580 | 2.3% | $216.85 | — | Common | 48576A100 |
| INSM | Insmed Incorporated | 529,743 | $11,178 | 2.3% | $19.24 | -1.4% | Common | 457669307 |
| XERS | Xeris Biopharma Holdings Inc | 3,974,999 | $10,414 | 2.1% | $2.55 | 0.0% | Common | 98422E103 |
| MDGL | Madrigal Pharmaceuticals inc | 38,011 | $8,781 | 1.8% | $132.25 | +104.8% | Common | 558868105 |
| CRNX | Crinetics Pharmaceuticals Inc. | 479,053 | $8,633 | 1.7% | $21.22 | -6.0% | Common | 22663K107 |
| TVTX | Travere Therapeutics Inc. | 552,846 | $8,492 | 1.7% | $18.49 | -1.6% | Common | 89422G107 |
| RVMD | Revolution Medicines, Inc. | 273,408 | $7,314 | 1.5% | $26.97 | -9.0% | Common | 76155X100 |
| HOWL | Werewolf Therapeutics, Inc. | 2,388,011 | $7,283 | 1.5% | $13.70 | -79.4% | Common | 95075A107 |
| KALV | Kalvista Pharmaceuticals Inc | 761,538 | $6,854 | 1.4% | $9.22 | 0.0% | Common | 483497103 |
| AXSM | Axsome Therapeutics, Inc. | 93,586 | $6,725 | 1.4% | $64.41 | +14.5% | Common | 05464T104 |
| FOLD | Amicus Therapeutics Inc. | 516,139 | $6,483 | 1.3% | $10.65 | +11.4% | Common | 03152W109 |
| — | Avadel Pharmaceuticals PLC | 384,990 | $6,345 | 1.3% | $16.48 | — | Sponsored ADR | 05337M104 |
| VRDN | Viridian Therapeutics Inc | 255,323 | $6,074 | 1.2% | $25.65 | 0.0% | Common | 92790C104 |
| EWTX | Edgewise Therapeutics Inc | 712,798 | $5,524 | 1.1% | $8.43 | 0.0% | Common | 28036F105 |
| ADAPY | Adaptimmune Therapeutics plc | 5,095,912 | $4,714 | 0.9% | $0.93 | — | Common | 00653A107 |
| OLMA | Olema Pharmaceuticals, Inc. | 462,500 | $4,176 | 0.8% | $6.04 | 0.0% | Common | 68062P106 |
| PHAT | Phathom Pharmaceuticals inc | 282,332 | $4,043 | 0.8% | $14.52 | -20.6% | Common | 71722W107 |
| — | Harpoon Therapeutics, Inc. | 3,196,707 | $2,270 | 0.5% | $14.79 | — | Common | 41358P106 |
| — | Inozyme Pharma Inc. | 326,921 | $1,821 | 0.4% | $7.14 | — | Common | 45790W108 |
| VTYX | Ventyx Biosciences Inc | 31,747 | $1,041 | 0.2% | $34.47 | 0.0% | Common | 92332V107 |
| — | Oncorus, Inc. | 2,377,031 | $96 | 0.0% | $32.33 | — | Common | 68236R103 |